Robert R. Singhaus

Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M. Ramanjulu, G. Scott Pesiridis, Jingsong Yang et al. · Nature · 2018 · 803 citations

Systemic Activity, Medicine, Mechanism Of Action +4

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Philip A. Harris, Scott B. Berger, Jae Uk Jeong et al. · Journal of Medicinal Chemistry · 2017 · 464 citations · Full text

Drug Target, Immunology, Cell Death +22

The Identification and Pharmacological Characterization of 6-( <i>tert</i> -Butylsulfonyl)- <i>N</i> -(5-fluoro-1 <i>H</i> -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase

Pamela A. Haile, Bartholomew J. Votta, Robert W. Marquis et al. · Journal of Medicinal Chemistry · 2016 · 122 citations · Full text

3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists

Robert R. Singhaus, Ronald C. Bernotas, Robert J. Steffan et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 60 citations · Full text

Biochemistry, Medicine, Mechanism Of Action +4

Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis

Baihua Hu, Michael D. Collini, Rayomand J. Unwalla et al. · Journal of Medicinal Chemistry · 2006 · 50 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Science +14